Oncology and Hematology

Episodes 161-176 of 300

Addressing Unmet Needs in Chronic GVHD Care with Preventative & Telemedicine Strategies
Addressing Unmet Needs in Chronic GVHD Care with Preventative & Telemedicine Strategies
Project Oncology®
Addressing Unmet Needs in Chronic GVHD Care with Preventative & Telemedicine Strategies
- Arpita Gandhi, MD, MS
How New Therapies & Patient Characteristics Guide cGVHD Treatment Sequencing
How New Therapies & Patient Characteristics Guide cGVHD Treatment Sequencing
Project Oncology®
How New Therapies & Patient Characteristics Guide cGVHD Treatment Sequencing
- Charles Turck, PharmD, BCPS, BCCCP
- Doris M. Ponce, MD, MS
Early Intervention Strategies for Chronic GVHD: How to Take a Proactive & Multidisciplinary Approach
Early Intervention Strategies for Chronic GVHD: How to Take a Proactive & Multidisciplinary Approach
Project Oncology®
Early Intervention Strategies for Chronic GVHD: How to Take a Proactive & Multidisciplinary Approach
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
- Zach DeFilipp, MD
Applying Shared Decision-Making & a Multidisciplinary Approach to GVHD Care
Applying Shared Decision-Making & a Multidisciplinary Approach to GVHD Care
Project Oncology®
Applying Shared Decision-Making & a Multidisciplinary Approach to GVHD Care
- Charles Turck, PharmD, BCPS, BCCCP
- Doris M. Ponce, MD, MS
- Annie Im, MD
Treating Steroid-Refractory Chronic GVHD: How to Transition to Second-Line Therapy
Treating Steroid-Refractory Chronic GVHD: How to Transition to Second-Line Therapy
Project Oncology®
Treating Steroid-Refractory Chronic GVHD: How to Transition to Second-Line Therapy
- Charles Turck, PharmD, BCPS, BCCCP
- Ned Waller, MD, PhD, FACP
- George Chen, MD
Optimizing Outcomes in Steroid-Refractory Chronic GVHD with Early Intervention
Optimizing Outcomes in Steroid-Refractory Chronic GVHD with Early Intervention
Project Oncology®
Optimizing Outcomes in Steroid-Refractory Chronic GVHD with Early Intervention
- Charles Turck, PharmD, BCPS, BCCCP
- Erin Kopp, ACNP-BC
Poster Pearl: Improved Sensitivity of a Multi-Analyte Early Detection Test Based on Mutation, Methylation, Aneuploidy, & Protein Biomarkers
Poster Pearl: Improved Sensitivity of a Multi-Analyte Early Detection Test Based on Mutation, Methylation, Aneuploidy, & Protein Biomarkers
Project Oncology®
Poster Pearl: Improved Sensitivity of a Multi-Analyte Early Detection Test Based on Mutation, Methylation, Aneuploidy, & Protein Biomarkers
- Charles Turck, PharmD, BCPS, BCCCP
- Frank Diehl, PhD
How Does Symptom Severity Influence Choice of Frontline Therapy for a Patient with BRAF-Mutated Metastatic Melanoma?
How Does Symptom Severity Influence Choice of Frontline Therapy for a Patient with BRAF-Mutated Metastatic Melanoma?
MinuteCE®
How Does Symptom Severity Influence Choice of Frontline Therapy for a Patient with BRAF-Mutated Metastatic Melanoma?
0.50 program credits
- Jason J. Luke, MD, FACP
- Elizabeth Buchbinder, MD
0.50 program credits
Can You Use a Dual Checkpoint Inhibitor Regimen in an Unfit Patient With BRAF WT Metastatic Melanoma?
Can You Use a Dual Checkpoint Inhibitor Regimen in an Unfit Patient With BRAF WT Metastatic Melanoma?
MinuteCE®
Can You Use a Dual Checkpoint Inhibitor Regimen in an Unfit Patient With BRAF WT Metastatic Melanoma?
0.50 program credits
- Jason J. Luke, MD, FACP
- Elizabeth Buchbinder, MD
0.50 program credits
Frontline Treatment: A Patient With BRAF WT Metastatic Melanoma - What Is the Optimal ICI Regimen?
Frontline Treatment: A Patient With BRAF WT Metastatic Melanoma - What Is the Optimal ICI Regimen?
MinuteCE®
Frontline Treatment: A Patient With BRAF WT Metastatic Melanoma - What Is the Optimal ICI Regimen?
0.50 program credits
- Jason J. Luke, MD, FACP
- Elizabeth Buchbinder, MD
0.50 program credits
MinuteCE®
Metastatic Melanoma: Solving Clinical Dilemmas in Frontline ICI Treatment
0.50 credits 3 episodes
- Jason J. Luke, MD, FACP
- Elizabeth Buchbinder, MD
0.50 credits 3 episodes
Poster Pearl: Imaging-Based Localization for MCED Tests Yields Lower Diagnostic Burden
Poster Pearl: Imaging-Based Localization for MCED Tests Yields Lower Diagnostic Burden
Project Oncology®
Poster Pearl: Imaging-Based Localization for MCED Tests Yields Lower Diagnostic Burden
- Charles Turck, PharmD, BCPS, BCCCP
- Betsy O'Donnell, MD
Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
Project Oncology®
Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
- Vivek Subbiah, MD
Impact of Infertility & Elective Fertility Among Female Oncologists
Impact of Infertility & Elective Fertility Among Female Oncologists
Project Oncology®
Impact of Infertility & Elective Fertility Among Female Oncologists
- Emily MacDuffie, MD
Combating the Complexities of Cancer Care During Pregnancy
Combating the Complexities of Cancer Care During Pregnancy
Project Oncology®
Combating the Complexities of Cancer Care During Pregnancy
- Alison Wakoff Loren, MD, MSCE
Optimizing Quality & Safety Systems to Reduce the Risk of Patient Harm
Optimizing Quality & Safety Systems to Reduce the Risk of Patient Harm
Project Oncology®
Optimizing Quality & Safety Systems to Reduce the Risk of Patient Harm
- Jacob Sands, MD
- Joseph O. Jacobson, MD